The need to move from 6-minute walk distance to outcome trials in pulmonary arterial hypertension

European Respiratory Review

Volumn 22, Issue 130, 2013, Pages 487-494

  Gaine, Sean ^a   Simonneau, Gérald ^b  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b BICÊTRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSENTAN; MACITENTAN; PLACEBO; PROSTACYCLIN; SELEXIPAG; SILDENAFIL; TADALAFIL;

6 MINUTE WALK DISTANCE TEST; ADD ON THERAPY; CLINICAL ASSESSMENT TOOL; CLINICAL EVALUATION; DYSPNEA; EXERCISE TEST; HEART LUNG TRANSPLANTATION; HUMAN; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PROGNOSIS; PULMONARY HYPERTENSION; REPRODUCIBILITY; REVIEW; RISK FACTOR; SCLERODERMA; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VALIDATION PROCESS; BIOASSAY; CLINICAL TRIAL (TOPIC); DISEASE COURSE; EXERCISE TOLERANCE; HEMODYNAMICS; HYPERTENSION, PULMONARY; METHODOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; TIME; TREATMENT OUTCOME; WALKING;

CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; ENDPOINT DETERMINATION; EXERCISE TEST; EXERCISE TOLERANCE; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; PREDICTIVE VALUE OF TESTS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME; WALKING;

EID: 84888813398     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/09059180.00006213     Document Type: Review

References (33)

1. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996; 334: 296-301.
2. Rich S. The 6-minute walk test as a primary endpoint in clinical trials for pulmonary hypertension. J Am Coll Cardiol 2012; 60: 1202-1203.
3. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-1123.
4. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
5. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008; 117: 3010-3019.
6. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
7. Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009; 119: 2894-2903.
8. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-804.
9. McLaughlin VV, Badesch DB, Delcroix M, et al. Endpoints and clinical trial design in pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: Suppl. 1, S97-S107.
10. Fleming TR, Powers JH. Biomarkers and surrogate endpoints in clinical trials. Stat Med 2012; 31: 2973-2984.
11. Sullivan EJ. Clinical trial endpoints. U.S. Food and Drug Administration. www.fda.gov/downloads/Training/ ClinicalInvestigatorTrainingCourse/UCM283378.pdf Date last accessed: May 21, 2013.
12. Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: are we being misled? Ann Intern Med 1996; 125: 605-613.
13. Chua R, Keogh AM, Byth K, et al. Comparison and validation of three measures of quality of life in patients with pulmonary hypertension. Intern Med J 2006; 36: 705-710.
14. Frost AE, Langleben D, Oudiz R, et al. The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect. Vascul Pharmacol 2005; 43: 36-39.
15. Galie N, Rubin LJ, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008; 371: 2093-2100.
16. Snow JL, Kawut SM. Surrogate end points in pulmonary arterial hypertension: assessing the response to therapy. Clin Chest Med 2007; 28: 75-89.
17. Barst RJ, Oudiz RJ, Beardsworth A, et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. J Heart Lung Transplant 2011; 30: 632-643.
18. Rubin LJ. The 6-minute walk test in pulmonary arterial hypertension: how far is enough?Am J Respir Crit Care Med 2012; 186: 396-397.
19. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008; 149: 521-530.
20. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-492.
21. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
22. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-788.
23. Humbert M, Sitbon O, Chaouat A, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation 2010; 122: 156-163.
24. Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007; 153: 1037-1047.
25. Fritz JS, Blair C, Oudiz RJ, et al. Baseline and follow-up 6-min walk distance and brain natriuretic peptide predict 2-year mortality in pulmonary arterial hypertension. Chest 2013; 143: 315-323.
26. Benza RL, Gomberg-Maitland M, Naeije R, et al. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant 2011; 30: 982-989.
27. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004; 169: 441-447.
28. Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed. Am Heart J 2010; 159: 245-257.
29. Savarese G, Paolillo S, Costanzo P, et al. Do changes of 6-minute walk distance predict clinical events in patients with pulmonary arterial hypertension? A meta-analysis of 22 randomized trials. J Am Coll Cardiol 2012; 60: 1192-1201.
30. Gabler NB, French B, Strom BL, et al. Validation of 6-minute walk distance as a surrogate end point in pulmonary arterial hypertension trials. Circulation 2012; 126: 349-356.
31. Pulido T, Adzeriko I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369: 809-818.
32. McLaughlin VV. Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011; 20: 262-269.
33. ClinicalTrials.gov. Selexipag (ACT-293987) in pulmonary arterial hypertension, GRIPHON trial. NCT01106014. http://clinicaltrials.gov/ct2/show/NCT01106014 Date last updated: September 3, 2013. Date last accessed: June 19, 2013.